AnaptysBio has reported that the ARISE-AD trial of its investigational B and T lymphocyte attenuator (BTLA) agonist, ANB032, ...

AnaptysBio, Inc. (NASDAQ:ANAB) announced that investigational ANB032, a BTLA agonist, did not meet the primary and secondary ...

Phase IIb study on ANAB's ANB032 for atopic dermatitis fails to meet goals. The company decides to discontinue any further investment in the candidate.

AnaptysBio is dropping its atopic dermatitis (AD) drug candidate after the compound failed to reduce eczema area and itch ...

San Diego, USA-based biotech AnaptysBio today announced that investigational ANB032, a BTLA agonist, did not meet the primary ...

AnaptysBio (ANAB) announced that investigational ANB032, a BTLA agonist, did not meet the primary and secondary endpoints in any of the doses ...

In a report released today, Emily Bodnar from H.C. Wainwright downgraded AnaptysBio (ANAB – Research Report) to a Hold, with a price target of ...

Return on Equity (ROE): AnaptysBio's ROE is below industry averages, indicating potential challenges in efficiently utilizing ...

AnaptysBio has been able to use its technology ... and strong activity in reducing pathogenic T-cells. ANB032, their BTLA agonist, is also in Phase 2b trials for atopic dermatitis.

ANB032, a BTLA agonist, is being evaluated for its ... LLY), neither of which are rated by BTIG. Despite this, AnaptysBio's management maintains that similar efficacy and safety to Dupixent ...

ANB032, a BTLA agonist, is being evaluated for its efficacy in treating ... LLY), neither of which are rated by BTIG. Despite this, AnaptysBio's management maintains that similar efficacy and safety ...